Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Brian G. Weinshenker, L Szczechowski et al.|The Lancet Neurology|2020Cited by 495
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Vitamin D, smoking, EBV, and long-term cognitive performance in MSMarianna Cortese, Kassandra L. Munger, Elena H. Martínez-Lapiscina et al.|Neurology|2020Cited by 58
Survival after palliative radiation therapy for cancer: The METSSS modelNicholas G. Zaorsky, Ming Wang, Menglu Liang et al.|Radiotherapy and Oncology|2021Cited by 23
Vitamin D and Tobacco Use and Long-Term Clinical and MRI Outcomes among CIS patients: 11-year Follow-up of BENEFIT. (P5.2-003)Elena H. Martínez‐Lapiscina, Alberto Ascherio, Kassandra L. Munger et al.|Neurology|2019Cited by 0